Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer J Clin. 2024;74:12–49.
Descamps G, Karaca Y, Lechien JR, Kindt N, Decaestecker C, Remmelink M, et al. Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients. J Cancer Res Clin Oncol. 2016;142:2185–96.
Google Scholar
Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18:269–82.
Google Scholar
Huang SH, Xu W, Waldron J, Siu L, Shen X, Tong L, et al. Refining American Joint Committee on cancer/union for international cancer control TNM stage and prognostic groups for human papillomavirus–related oropharyngeal carcinomas. J Clin Oncol. 2015;33:836–45.
Google Scholar
Grünwald V, Chirovsky D, Cheung WY, Bertolini F, Ahn MJ, Yang MH, et al. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results of the GLANCE H&N study. Oral Oncol. 2020;102:104526.
Google Scholar
Harrington, Burtness KJ, Greil B, Soulières R, Tahara D, Castro M, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol. 2023;41:790–802.
Google Scholar
Tahara M, Greil R, Rischin D, Harrington KJ, Burtness B, Castro GD, et al. 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048. Ann Oncol. 2022;33:S844.
Google Scholar
Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:NEJMoa1602252–1867.
Google Scholar
Cohen EW, Souliéres D, Tourneau CL, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. The Lancet. 2018 Nov 29;1–12. https://doi.org/10.1016/s0140-6736(18)31999-8.
Rubin EJ, Yeku OO, Morrissey S NEJM at ESMO – Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2024. https://doi.org/10.1056/nejme2411489 PubMed PMID: 39282920.
Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90.
Google Scholar
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
Google Scholar
Grimm MO, Esteban E, Barthélémy P, Schmidinger M, Busch J, Valderrama BP, et al. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2023;24:1252–65.
Google Scholar
Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, et al. Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2023;24:347–59.
Google Scholar
Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, et al. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol. 2022;40:2913–23.
Google Scholar
Machiels JP, Leemans CR, Golusinski W, Grau C, Licitra L, Gregoire V, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up † † These Guidelines were developed by the European Head and Neck Society (EHNS), the European Society for Medical Oncology (ESMO) and the European SocieTy for Radiotherapy & Oncology (ESTRO). The three societies nominated authors to write the guidelines as well as reviewers to comment on them. These guidelines were approved by the EHNS Executive Board, the ESMO Guidelines Committee and the ESTRO Executive Board in June 2020. Ann Oncol. 2020;31:1462–75.
Google Scholar
Couteau C, Chouaki N, Leyvraz S, Oulid-Aissa D, Lebecq A, Domenge C, et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 1999;81:457–62.
Google Scholar
Klinghammer K, Gauler T, Dietz A, Grünwald V, Stöhlmacher J, Knipping S, et al. Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108). Eur J Cancer. 2019;122:53–60.
Google Scholar
Saleh K, Daste A, Martin N, Pons-Tostivint E, Auperin A, Herrera-Gomez RG, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer Oxf Engl 1990. 2019;121:123–9.
Google Scholar
Siu LL, Even C, Mesia R, Remenar E, Daste A, Delord JP, et al. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC. JAMA Oncol. 2018 Nov 1;1–9. https://doi.org/10.1001/jamaoncol.2018.4628.
Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019;107:142–52.
Google Scholar
Cabezas, Camarero, Cabrera S, Martín, Merino MN, Menéndez, et al. Safety and efficacy of cetuximab-based salvage chemotherapy after checkpoint inhibitors in head and neck cancer. Oncol. 2021;26:e1018–35.
Google Scholar
Opzoomer JW, Sosnowska D, Anstee JE, Spicer JF, Arnold JN. Cytotoxic chemotherapy as an immune stimulus: a molecular perspective on turning up the immunological heat on cancer. Front Immunol. 2019;10:1654.
Google Scholar
Sukari A, Nagasaka M, Abdallah N. Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors. Oral Oncol. 2018;80:100–2.
Google Scholar
Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31:942–50.
Google Scholar
Fuereder T, Klinghammer K, Hahn DA, Grünberger B, Melchardt T, Greil R, et al. 880P Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: primary analysis from the PACE ACE trial. Ann Oncol. 2024;35:S629.
Google Scholar
Wakasaki T, Manako T, Yasumatsu R, Hara H, Toh S, Masuda M, et al. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study. PLoS ONE. 2022;17:e0271907.
Google Scholar
Guiard E, Clatot F, Even C, Perréard M, Abdeddaim C, Johnson A, et al. Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma. Eur J Cancer. 2021;159:125–32.
Google Scholar
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, et al. Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651. J Clin Oncol. 2023;41:2166–80.
Google Scholar
Psyrri A, Fayette J, Harrington K, Gillison M, Ahn MJ, Takahashi S, et al. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Ann Oncol. 2023;34:262–74.
Google Scholar
Burtness, Harrington B, Greil KJ, Soulières R, Tahara D, Castro M, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–28.
Google Scholar
Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, et al. Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck. JAMA Oncol. 2023;9:779–89.
Google Scholar
